Form 4: Entrada Therapeutics Exec Granted Equity, Sells for Tax

Entrada Therapeutics' President of Research & Development, Natarajan Sethuraman, received new equity grants and executed non-discretionary stock sales to cover tax obligations.

Summary

• Natarajan Sethuraman, President, Research & Development at Entrada Therapeutics, Inc. (TRDA), was granted 55,800 Restricted Stock Units (RSUs) on March 1, 2026.
• Each RSU represents the contingent right to receive one share of common stock, vesting 25% annually from March 1, 2027, to March 1, 2030, contingent on continued employment.
• An additional 83,200 stock options were granted on March 1, 2026, with an exercise price of $11.93.
• These stock options vest 25% on March 1, 2027, with the remaining 75% vesting in 36 equal monthly installments thereafter, fully vested by March 1, 2030.
• Sethuraman disposed of 3,898 shares of common stock on March 2, 2026, at a weighted average price of $11.6579 to cover minimum statutory tax withholding obligations.
• An additional 7,577 shares of common stock were disposed of on March 3, 2026, at a weighted average price of $11.7564, also for tax withholding purposes.
• Following these transactions, Sethuraman beneficially owns 242,224 shares of common stock and 83,200 derivative securities (stock options).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive event, reflecting standard executive compensation practices that align management incentives with long-term company performance, despite the non-discretionary tax-related sales.

Positives

• The grant of 55,800 Restricted Stock Units (RSUs) and 83,200 stock options aligns management's long-term interests with those of shareholders, incentivizing performance and retention.
• The equity grants demonstrate continued commitment to the executive team and confidence in the company's future trajectory.

Negatives

• The sale of 11,475 shares of common stock, totaling approximately $134,700, reduces the executive's direct shareholding, although these were non-discretionary sales for tax purposes.

Future Outlook

The future outlook for Natarajan Sethuraman's equity holdings is tied to the vesting schedules of the granted RSUs and stock options, which will vest incrementally through March 1, 2030, contingent on continued service to Entrada Therapeutics.

Industry Context

StockSavvy.ai notes that routine equity grants to executives, particularly in the biotechnology sector, are a common practice to attract, retain, and incentivize key talent. These grants typically include multi-year vesting schedules to ensure long-term alignment with company performance and shareholder value creation. The associated 'sell-to-cover' transactions for tax obligations are also standard and do not reflect a discretionary sale by the executive.

Comparison to Industry Standards

• Executive compensation packages in the biotechnology industry frequently include a significant equity component, similar to Entrada Therapeutics' grants to its President of Research & Development.
• Vesting schedules extending over several years (e.g., 3-4 years) are standard across the industry for both RSUs and stock options, aiming to foster long-term commitment and performance, comparable to practices at companies like Moderna or BioNTech for their senior scientific leadership.
• The 'sell-to-cover' mechanism for tax withholding is a widely adopted practice for equity awards across all industries, including tech and pharma, and is not indicative of a unique or unusual financial event for Entrada Therapeutics.

Stakeholder Impact

• Shareholders: The equity grants align the executive's interests with shareholders, potentially fostering long-term value creation. The tax-related sales are minor and non-discretionary, having minimal impact.
• Employees: The compensation structure for a key executive may set a precedent or reflect the company's overall approach to incentivizing its talent.

Next Steps

• The granted Restricted Stock Units (RSUs) will vest 25% annually on March 1, 2027, March 1, 2028, March 1, 2029, and March 1, 2030.
• The granted stock options will vest 25% on March 1, 2027, with the remaining 75% vesting in 36 equal monthly installments thereafter, fully vested by March 1, 2030.

Key Dates

Keywords

Entrada Therapeutics, TRDA, Natarajan Sethuraman, Restricted Stock Units, RSUs, Stock Options, Insider Trading, Equity Grant, Executive Compensation, Biotechnology, Pharmaceuticals